Search
The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:
Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.
Anthony DeMaio spent much of his younger life hiding from the spotlight. Today, he lives authentically in his personal and professional life. He also embraces the spotlight more figuratively — through a number of appearances on the small screen.
New MSK research finds skin stem cells retain long-lasting memory of inflammation; shows how a large cancer DNA study could transform personalized oncology; reveals how the protein BAF helps cancer cells hide from the immune system; and investigates how early DNA markings shape cell fate.
See how the MSK Kids Class of 2020 celebrated their high school graduation.
MSK Kids celebrated the Class of 2021 at its 15th Annual Convocation Ceremony on June 10.
After graduate student Irene Dimatulac was diagnosed with osteosarcoma in her knee, treatment at MSK — and support from MSK’s Adolescent and Young Adult Program — allowed her to get back to her life.
Después de que a la estudiante de posgrado Irene Dimatulac le diagnosticaran osteosarcoma en la rodilla, el tratamiento en MSK —y el apoyo del Programa para Adolescentes y Adultos Jóvenes de MSK— le permitieron volver a su vida.
MSK doctors, such as Julia Glade Bender, are achieving better outcomes for patients by personalizing treatment on the basis of the biology of the cancer rather than the patient’s age.